MedTrace Logo

Multi-center Study to Investigate the Effects of Citrasate® on Heparin N Requirements During Hemodialysis Treatment

NCT01092455 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2011-09-02

No results posted yet for this study

Summary

The purpose of this study is to determine whether the use of Citrasate®, citric acid dialysate enables the reduction of the heparin N (anticoagulant) dose in patients undergoing hemodialysis.

Conditions

  • Renal Dialysis

Interventions

DRUG

Heparin N reduction

Dialysis with Citrasate, acid concentrate plus 100% of patient's standard heparin N dose; Dialysis with Citrasate acid concentrate plus 80% of patient's standard heparin N dose; Dialysis with Citrasate acid concentrate plus 66.7% of patient's standard heparin N dose.

Sponsors & Collaborators

  • Randolph Quinn

    lead INDUSTRY

Principal Investigators

  • Jeffrey J Sands, MD MMM · Fresenius Medical Care North America

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2010-06-30
Completion
2010-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01092455 on ClinicalTrials.gov